Novel Glutamatergic Treatments for Severe Mood Disorders. - Wikidata - wikimedia - TriplyDB

Novel Glutamatergic Treatments for Severe Mood Disorders.

Novel Glutamatergic Treatments for Severe Mood Disorders.

http://www.wikidata.org/entity/Q36498659

about

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism Investigational drugs in recent clinical trials for treatment-resistant depression.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis.Upregulation of prefrontal metabotropic glutamate receptor 5 mediates neuropathic pain and negative mood symptoms after spinal nerve injury in rats.Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.Glutamatergic Modulators in Depression.Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex as a Molecular Determinant of Pain and Ensuing Depression Parkinson's disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons

P2860

Q33842686-07E54235-3DFA-40AD-BC42-3E4CAAD9A03A Q34549390-BAA6774C-AA69-4724-8629-0633A3190707 Q34551188-03A19BC4-C5F6-4C7D-8F1A-B964AB0C09B6 Q37490329-E236723C-7E21-4F5A-858F-0B3525C1DA94 Q38603032-EA7FC457-7BB5-4B47-B7DF-E9994C7D2288 Q38838637-CDA9AA59-E430-472C-A1EF-ACB30E40ED3A Q47306135-9E3D99C5-7FAB-4BE9-B14F-E3E9410DC95D Q47382890-42B0F6B6-F90E-4E02-82BE-6C1AEF205E86 Q49712849-6E072A9A-8888-4B8A-84BC-15ED0AC29C9B Q57817547-D2A3D8E5-0582-41DE-8AEA-25C351A6C72D Q58756675-57A00DAE-59A4-4316-82F8-CB8375283050

P2860

Novel Glutamatergic Treatments for Severe Mood Disorders.

http://www.wikidata.org/entity/Q36498659

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Novel Glutamatergic Treatments for Severe Mood Disorders.

@ast

Novel Glutamatergic Treatments for Severe Mood Disorders.

@en

type

label

Novel Glutamatergic Treatments for Severe Mood Disorders.

@ast

Novel Glutamatergic Treatments for Severe Mood Disorders.

@en

prefLabel

Novel Glutamatergic Treatments for Severe Mood Disorders.

@ast

Novel Glutamatergic Treatments for Severe Mood Disorders.

@en

P1433

Q36498659-E0CFC610-5715-484B-88F6-5831A2A7BE21

P1476

Q36498659-F5495F74-E2EB-4456-8626-C642D0BD08A1

P2093

Q36498659-39647934-EBC2-463C-9240-6B6BDDFE7E8D

Q36498659-ED39E02E-AA7D-431B-A1FF-7A241E84CABB

Q36498659-F151F09B-6385-4C6B-9BB8-D9D12CAC2983

P2860

Q36498659-008B3A28-69FA-4667-B01C-DF84A37E53B2

Q36498659-095C46B9-F77B-4DDA-A172-A96AF6D0FC36

Q36498659-0C935D16-E05A-44B2-96D8-1AC23DBD5030

Q36498659-0D3E7591-86F9-40D9-948D-4A14AFFECBE5

Q36498659-10AAD862-D144-4598-AF4B-87D75AA2C484

Q36498659-149C551F-31DE-449D-9307-321FE6952C25

Q36498659-18375821-E742-409C-8A9E-AC8943234895

Q36498659-1A528253-3F05-4463-B74D-7DB116E4575E

Q36498659-1BC3EFAD-44A6-4A9E-B623-F705EDC46657

Q36498659-1D0FFF05-338A-454B-979D-987C147ADD25

P2888

Q36498659-7107C129-B45C-4A33-A770-973414FD3346

P304

Q36498659-2706F27C-90A6-4704-A1EE-F90DBDC422B4

P31

Q36498659-95743167-4AF8-4948-8205-C53BFA731CC9

P356

Q36498659-8BC6895D-596B-460C-BC68-18A30883FC72

P433

Q36498659-6E694B72-6CF5-4D6F-8DE8-EF0F8C42CE50

P478

Q36498659-DC795D62-3C6C-468A-9B9A-3D484D9D3E88

P577

Q36498659-ECC9D690-05B3-4A38-9725-6EB967B07AED

P5875

Q36498659-9CAADDAC-2C90-46F7-AE92-0167C2BE40D3

P698

Q36498659-91D07CD0-8DD3-4A9D-8997-24DEBCE872D3

P932

Q36498659-83DCD82A-F19F-48E5-B085-2E5136382B12

P356

S40473-015-0050-5

P1433

Current behavioral neuroscience reports

P1476

Novel Glutamatergic Treatments for Severe Mood Disorders.

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Mark J Niciu

http://www.w3.org/2001/XMLSchema#string

Minkyung Park

http://www.w3.org/2001/XMLSchema#string

P2860

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Grand challenges in global mental health

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins

Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression

Treatment-resistant depression: critique of current approaches

P2888

s40473-015-0050-5

P304

198-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40473-015-0050-5

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283154857

http://www.w3.org/2001/XMLSchema#string

P698

26824031

http://www.w3.org/2001/XMLSchema#string

P932

4725605

http://www.w3.org/2001/XMLSchema#string